 HAIFA, Israel, Dec. 09, 2020 GLOBE NEWSWIRE -- Pluristem Therapeutics Inc. Nasdaq:PSTI TASE:PSTI, a leading regenerative medicine company developing a platform of novel biological therapeutic products, today announced that the independent Data Monitoring Committee DMC of its global pivotal Phase III study for the treatment of critical limb ischemia CLI issued its recommendation letter following the interim analysis. The clinical dataset was reviewed by the independent DMC for safety and analysis of the primary endpoint of amputation-free survival, defined as time to occurrence of major amputation of the index leg or death. 